Table 1.

Summary of sublingual immunotherapy meta-analyses

Study	Trials/patients	Disease	Results, SMD (95% confidence interval)
Wilson et al15	22/979	AR	Symptoms −0.42 (−0.69 to −0.15; P = 0.002), medication use −0.43 (−0.63 to −0.23; P = 0.00003)
Penagos et al16	10/484	AR	Symptoms −0.56 (−1.01 to −0.10; P = 0.02), medication use −0.76 (−1.46 to −0.06; P = 0.03)
Olaguíbel et al17	7/256	ARC, asthma	Symptoms AR −0.44 (−1.22 to 0.3; P = 0.27), symptoms AC −1.49 (−3.69 to 0.72; P = 0.19), symptoms asthma −1.42 (−2.51 to −0.34; P = 0.01), medication use −1.01 (−2.06 to 0.04; P = 0.06)
Compalati et al18	8/382	AR	Symptoms −0.95 (−1.77 to −0.14; P = 0.02), medication use −1.88 (−3.65 to −0.12; P = 0.04)
	9/452	Asthma	Symptoms −0.95 (−1.74 to −0.15; P = 0.02), medication use −1.48 (−2.70 to −0.26; P = 0.02)
Radulovic et al23	49/4589	AR	Symptoms −0.49 (−0.64 to −0.34; P < 0.00001), medication use −0.32 (−0.43 to −0.21; P < 0.00001)
Calderon et al24	42/3958	AC	Symptoms −0.41 (−0.53 to −0.28; P < 0.00001), medication use −0.10 (−0.22 to 0.03; P = 0.13)
Penagos et al26	9/441	Asthma	Symptoms −1.14 (−2.1 to −0.18; P = 0.02), medication use −1.63 (−2.83 to −0.44; P = 0.007)
Dretzke et al27	42	AR	Symptoms −0.33 (−0.42 to −0.25; P < 0.00001), medication use −0.27 (−0.37 to −0.17; P < 0.00001)

Abbreviations: SMD, standardized mean difference; AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AC, allergic conjunctivitis.